Integra LifeSciences Reports Q4'2025 Earnings

Got story updates? Submit your updates here. ›

Integra LifeSciences, a leading medical technology company, reported its fourth quarter and full-year 2025 financial results. The company delivered revenue and adjusted earnings per share (EPS) in line with its guidance, despite ongoing remediation efforts and supply constraints. Integra's Codman Specialty Surgical segment saw growth against a strong prior-year comparison, while the Tissue Technologies segment was impacted by the MediHoney product and a difficult prior-year comparison for Integra Skin. The company also provided its outlook for the first quarter and full-year 2026, reflecting strengthening of the foundation and solid underlying demand.

Why it matters

Integra LifeSciences' Q4 2025 results and 2026 outlook provide insights into the company's progress in building a sustainable foundation for growth and profitability. The report highlights Integra's efforts to improve quality, supply chain reliability, and operational execution, which are critical for the company's long-term success in the medical technology industry.

The details

In the fourth quarter of 2025, Integra reported revenue of $434.9 million, a 1.7% decrease compared to the prior-year period. Adjusted EPS was $0.83, a 14.4% decline year-over-year. For the full-year 2025, the company reported revenue of $1.635 billion, a 1.5% increase, and adjusted EPS of $2.23, a 12.9% decrease compared to 2024. The company's Codman Specialty Surgical segment saw growth in neurosurgery instruments, ENT, and international markets, while the Tissue Technologies segment was impacted by the MediHoney product and a difficult prior-year comparison for Integra Skin. Integra also provided its outlook for the first quarter and full-year 2026, expecting reported revenue growth of 1.6% to 4.1% and adjusted EPS of $2.30 to $2.40 for the full year.

• Integra LifeSciences reported its fourth quarter and full-year 2025 financial results on February 26, 2026.